• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Champions Oncology Inc.

    2/12/24 9:12:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSBR alert in real time by email
    SC 13G 1 d10972643_13-g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Champions Oncology, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    15870P307
    (CUSIP Number)

     

     

    December 28, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ] Rule 13d-1(b)

     

    [x] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No 15870P307    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Tocqueville Asset Management LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      684,578  
         
    6. SHARED VOTING POWER  
         
       0  
         
    7. SOLE DISPOSITIVE POWER  
         
      684,578  
         
    8. SHARED DISPOSITIVE POWER  
         
       0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      684,578  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.0%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA  

     

     
     

     

     

     

    CUSIP No 15870P307  

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Taubenpost Capital L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      684,578  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      684,578  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      684,578  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.0%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  

     

     

     

     

     
     

     

    CUSIP No 15870P307  

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Taubenpost Capital LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      684,578  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      684,578  
         
    8. SHARED DISPOSITIVE POWER  
         
      0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      684,578  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.0%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      HC, OO  

     

     

     

     
     

     

    CUSIP No 15870P307  

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Donald Wang  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [  ]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      684,578  
         
    6. SHARED VOTING POWER  
         
      0  
         
    7. SOLE DISPOSITIVE POWER  
         
      684,578  
         
    8. SHARED DISPOSITIVE POWER  
         
       0  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      684,578  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.0%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  

     

     

     
     

     

     

     

    CUSIP No 15870P307    

     

    Item 1. (a). Name of Issuer:  
           
        Champions Oncology, Inc.  
           
      (b). Address of Issuer’s Principal Executive Offices:  
           
        One University Plaza, Suite 307
    Hackensack, New Jersey 07601
     
           
    Item 2. (a). Name of Person Filing:  
           
       

    Tocqueville Asset Management LP

    Taubenpost Capital L.P.

    Taubenpost Capital LLC

    Donald Wang

     
           
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Tocqueville Asset Management LP

    40 West 57th Street, 19th Floor
    New York, NY 10019

     
           
      (c) Citizenship:  
           
       

    Tocqueville Asset Management LP – Delaware

    Taubenpost Capital L.P. - Delaware

    Taubenpost Capital LLC - Delaware

    Donald Wang – United States of America

     
           
      (d).   Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  
           
      (e). CUSIP Number:  
           
        15870P307  
           

     

     
     

     

     

     


    Item 3.
    If This Statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
           
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [  ] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_]

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k)   [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    Tocqueville Asset Management LP – 684,578

    Taubenpost Capital L.P. - 684,578

    Taubenpost Capital LLC - 684,578

    Donald Wang – 684,578

         
      (b)   Percent of class:
         
       

    Tocqueville Asset Management LP – 5.0%

    Taubenpost Capital L.P. - 5.0%

    Taubenpost Capital LLC - 5.0%

    Donald Wang – 5.0%

         
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote    
               
         

    Tocqueville Asset Management LP – 0

    Taubenpost Capital L.P. - 0

    Taubenpost Capital LLC - 0

    Donald Wang – 0

     
             
        (ii)   Shared power to vote or to direct the vote    
               
         

    Tocqueville Asset Management LP – 684,578

    Taubenpost Capital L.P. - 684,578

    Taubenpost Capital LLC - 684,578

    Donald Wang – 684,578

     
             
        (iii) Sole power to dispose or to direct the disposition of    
               
         

    Tocqueville Asset Management LP – 0

    Taubenpost Capital L.P. - 0

    Taubenpost Capital LLC - 0

    Donald Wang – 0

     
             
        (iv)   Shared power to dispose or to direct the disposition of    
               
         

    Tocqueville Asset Management LP – 684,578

    Taubenpost Capital L.P. - 684,578

    Taubenpost Capital LLC - 684,578

    Donald Wang – 684,578

     
                 

     

     
     

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

     

      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      The securities reported in this Schedule 13G that are beneficially owned by Tocqueville Asset Management LP, are directly owned by advisory clients of Tocqueville Asset Management LP.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      Please see Exhibit B Attached hereto.
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       

    Item 10.

    Certification.

       
     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Tocqueville Asset Management LP*

     

    By: /s/ Kelsey Graham

    Title: Chief Compliance Officer

     

     

    Taubenpost Capital L.P.*

    By Taubenpost Capital LLC, its General Partner

     

    By: /s/ Donald Wang

    Title: Managing Member

     

     

    Taubenpost Capital LLC*

     

    By: /s/ Donald Wang

    Title: Chief Compliance Officer

     

     

    Donald Wang*

     

    By: /s/ Donald Wang

    Signature

     

     

    Date: February 12, 2024

     

    *The Reporting Persons disclaim beneficial ownership in the shares reported herein except to the extent of their pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G filing dated February 12, 2024 relating to the Common Stock of Champions Oncology, Inc. shall be filed on behalf of the undersigned.

     

    Tocqueville Asset Management LP

     

    By: /s/ Kelsey Graham

    Title: Chief Compliance Officer

     

     

    Taubenpost Capital L.P.

    By Taubenpost Capital LLC, its General Partner

     

    By: /s/ Donald Wang

    Title: Managing Member

     

     

    Taubenpost Capital LLC

     

    By: /s/ Donald Wang

    Title: Chief Compliance Officer

     

     

    Donald Wang

     

    By: /s/ Donald Wang

    Signature

     

     
     

     

     

     

     

    Exhibit B

    Taubenpost Capital L.P. is the relevant entity for which each of Taubenpost Capital LLC and Donald Wang may be considered a control person.

     

     

    Get the next $CSBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSBR

    DatePrice TargetRatingAnalyst
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $CSBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Financials

    Live finance-specific insights

    See more
    • Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

      HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024.Second Quarter and Recent Highlights:Total revenue increased 17% to $13.5 millionGross profit of $6.1 million; margin of 45%Net income of approximately $730,000Adjusted EBITDA of $1.1 millionDevelopment of new data revenue streamFirst Half 2025 Highlights:Total revenue increased 14% to $27.6 millionGross profit of $13.1 million; margin of 47%Net income of $2.1 millionAdjusted EBITDA of $3.2 millionRonni

      12/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

      HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or

      12/5/24 4:30:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

      HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.First Quarter Highlights:Total revenue increased 12% to $14.1 millionMargin improved to 50%Adjusted EBITDA of $2.0 millionNet income of $1.3 millionRonnie Morris, CEO of Champions, commented, "As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided

      9/11/24 4:00:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Champions Oncology Inc.

      SC 13G/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      11/14/24 9:53:10 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Champions Oncology Inc. (Amendment)

      SC 13D/A - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      5/6/24 7:46:06 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Champions Oncology Inc.

      SC 13G - CHAMPIONS ONCOLOGY, INC. (0000771856) (Subject)

      2/12/24 9:12:00 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mendelson Daniel Newman bought $6,500 worth of shares (1,000 units at $6.50), increasing direct ownership by 0.51% to 198,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/16/24 11:45:44 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $12,540 worth of shares (2,000 units at $6.27), increasing direct ownership by 1% to 197,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/12/24 12:47:07 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mendelson Daniel Newman bought $18,577 worth of shares (2,944 units at $6.31), increasing direct ownership by 2% to 195,625 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      1/11/24 10:57:35 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Breitfeld Philip P. disposed of 4,150 shares, decreasing direct ownership by 42% to 5,717 units (SEC Form 4)

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      4/2/25 4:20:36 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Breitfeld Philip P.

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 12:14:09 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sidransky David

      4 - CHAMPIONS ONCOLOGY, INC. (0000771856) (Issuer)

      11/18/24 11:47:41 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Champions Oncology upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Champions Oncology from Hold to Buy and set a new price target of $6.00

      9/12/24 9:23:16 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roth Capital reiterated coverage on Champions Oncology with a new price target

      Roth Capital reiterated coverage of Champions Oncology with a rating of Buy and set a new price target of $16.00 from $13.50 previously

      3/15/21 10:03:32 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    Leadership Updates

    Live Leadership Updates

    See more
    • Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

      HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy.The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities. The continued investment in this clinical portfolio of serv

      1/8/25 8:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces the Addition of Brady Davis as President

      HACKENSACK, NJ / ACCESSWIRE / October 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, has appointed Brady Davis as President to continue to develop new strategic initiatives to drive accelerated growth."We are thrilled to have Brady join the already incredibly talented team here at Champions Oncology. Brady has deep healthcare, data and oncology-specific experience and has a proven track record of building products and solutions that align with customer needs," stated Ronnie Morris, CEO of Champions Oncology.Mr. Davis brings more than 25 years of international experience leading medical

      10/17/23 8:30:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Announces Addition to Board of Directors

      HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to announce the appointment of Rob Brainin to its Board of Directors. Rob is an experienced global life sciences and healthcare executive with more than 15 years of experience. His appointment will help guide the company's efforts to accelerate the development of its data platform for use in drug discovery. The Company also announced the resignation of current board member Abba Poliakoff. Joel Ackerman, Chairman of the Board of Directors commented

      2/22/21 9:00:00 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CSBR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/17/25 11:03:52 AM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Champions Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      3/11/25 4:32:41 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Champions Oncology Inc.

      10-Q - CHAMPIONS ONCOLOGY, INC. (0000771856) (Filer)

      12/16/24 4:16:03 PM ET
      $CSBR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care